Verheij Herman J
Pyxis Discovery, Delft, The Netherlands.
Mol Divers. 2006 Aug;10(3):377-88. doi: 10.1007/s11030-006-9040-6. Epub 2006 Sep 21.
High program failure rates in the pharmaceutical industry have prompted the development of predictive software that can profile compound libraries as being 'druglike' (resembling existing drugs) and/or 'leadlike' (possessing the structural and physicochemical profile of a quality lead). In recent years, these two notions prompted pharmaceutical companies to clean up their corporate libraries of screening compounds. In order to maintain and expand the size and diversity of these corporate libraries, pharmaceutical companies still continue to add compounds to these, mainly by the acquisition of screening libraries. In this paper, we have analyzed 45 commercially available libraries, offered by suppliers of screening chemistry, for leadlikeness and diversity of the offered structures. To this end we have used a set of structural and physicochemical filters for leadlikeness that was developed in-house. These 45 supplier libraries contained a total of 5.3 million structures, of which 49% (2,592,778 structures) turned out to be unique, and only 12% (677,328 structures) were found to be both unique and leadlike. A diversity analysis revealed that big differences exist between the various offered libraries.
制药行业中较高的项目失败率促使了预测软件的开发,该软件能够将化合物库描绘为“类药物的”(类似于现有药物)和/或“类先导物的”(具有优质先导物的结构和物理化学特征)。近年来,这两个概念促使制药公司清理其用于筛选化合物的公司库。为了维持和扩大这些公司库的规模及多样性,制药公司仍继续向其中添加化合物,主要是通过收购筛选库来实现。在本文中,我们分析了筛选化学供应商提供的45个商业可用库,以评估所提供结构的类先导物特征和多样性。为此,我们使用了一组内部开发的用于评估类先导物特征的结构和物理化学筛选标准。这45个供应商库总共包含530万个结构,其中49%(2592778个结构)被证明是独特的,只有12%(677328个结构)被发现既独特又具有类先导物特征。多样性分析表明,各个提供的库之间存在很大差异。